Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.

Awan FT, Thirman MJ, Patel-Donnelly D, Assouline S, Rao AV, Ye W, Hill B, Sharman JP.

Leuk Lymphoma. 2019 Jan 11:1-6. doi: 10.1080/10428194.2018.1562180. [Epub ahead of print]

PMID:
30633573
2.

Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma.

Bond DA, Dotson E, Awan FT, Baiocchi RA, Blum KA, Maddocks K.

Clin Lymphoma Myeloma Leuk. 2018 Nov 29. pii: S2152-2650(18)31581-7. doi: 10.1016/j.clml.2018.11.020. [Epub ahead of print] No abstract available.

PMID:
30594446
3.

Illness Perceptions in Chronic Lymphocytic Leukemia: Testing Leventhal's Self-regulatory Model.

Westbrook TD, Morrison EJ, Maddocks KJ, Awan FT, Jones JA, Woyach JA, Johnson AJ, Byrd JC, Andersen BL.

Ann Behav Med. 2018 Dec 26. doi: 10.1093/abm/kay093. [Epub ahead of print]

PMID:
30590383
4.

Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma.

Hashmi H, Hamadani M, Awan FT.

Expert Opin Pharmacother. 2018 Oct;19(15):1631-1634. doi: 10.1080/14656566.2018.1518430. Epub 2018 Sep 10. No abstract available.

PMID:
30200789
5.

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.

Rogers KA, Huang Y, Ruppert AS, Awan FT, Heerema NA, Hoffman C, Lozanski G, Maddocks KJ, Moran ME, Reid MA, Lucas M, Woyach JA, Whitlow WT, Jones JA, Byrd JC.

Blood. 2018 Oct 11;132(15):1568-1572. doi: 10.1182/blood-2018-05-853564. Epub 2018 Aug 15.

PMID:
30111609
6.

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.

Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, Goettl VM, Tran M, Harrington BK, Rogers KA, Awan FT, Maddocks K, Andritsos L, Lehman AM, Sampath D, Lapalombella R, Eathiraj S, Abbadessa G, Schwartz B, Johnson AJ, Byrd JC, Woyach JA.

Cancer Discov. 2018 Oct;8(10):1300-1315. doi: 10.1158/2159-8290.CD-17-1409. Epub 2018 Aug 9.

PMID:
30093506
7.

Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.

Guha A, Derbala MH, Zhao Q, Wiczer TE, Woyach JA, Byrd JC, Awan FT, Addison D.

J Am Coll Cardiol. 2018 Aug 7;72(6):697-698. doi: 10.1016/j.jacc.2018.06.002. No abstract available.

PMID:
30072003
8.

Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre.

Rogers KA, Huang Y, Dotson E, Lundberg J, Andritsos LA, Awan FT, Woyach JA, Byrd JC.

Br J Haematol. 2018 Jul 20. doi: 10.1111/bjh.15508. [Epub ahead of print] No abstract available.

PMID:
30028000
9.

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.

Trnĕný M, Verhoef G, Dyer MJ, Ben Yehuda D, Patti C, Canales M, Lopez A, Awan FT, Montgomery PG, Janikova A, Barbui AM, Sulek K, Terol MJ, Radford J, Guidetti A, Di Nicola M, Siraudin L, Hatteville L, Schwab S, Oprea C, Gianni AM.

Haematologica. 2018 Aug;103(8):1351-1358. doi: 10.3324/haematol.2017.168401. Epub 2018 May 10.

10.

Use of acalabrutinib in patients with mantle cell lymphoma.

Awan FT, Jurczak W.

Expert Rev Hematol. 2018 Jun;11(6):495-502. doi: 10.1080/17474086.2018.1473030. Epub 2018 May 14.

PMID:
29737219
11.

Choosing ibrutinib wisely.

Awan FT.

Blood. 2018 Jan 11;131(2):156-157. doi: 10.1182/blood-2017-11-813907. No abstract available.

12.

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.

Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, Rogers K, McCoy A, Mousa L, Guha A, Heerema NA, Maddocks K, Christian B, Andritsos LA, Jaglowski S, Devine S, Baiocchi R, Woyach J, Jones J, Grever M, Blum KA, Byrd JC, Awan FT.

Blood Adv. 2017 Sep 8;1(20):1739-1748. doi: 10.1182/bloodadvances.2017009720. eCollection 2017 Sep 12.

13.

A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.

Rogers KA, Huang Y, Ruppert AS, Salem G, Stephens DM, Heerema NA, Andritsos LA, Awan FT, Byrd JC, Flynn JM, Maddocks KJ, Jones JA.

Br J Haematol. 2018 Jan;180(2):259-266. doi: 10.1111/bjh.15035. Epub 2017 Nov 28.

PMID:
29193006
14.

Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?

Mina A, Sandoval Sus J, Sleiman E, Pinilla-Ibarz J, Awan FT, Kharfan-Dabaja MA.

Blood Rev. 2018 Mar;32(2):159-166. doi: 10.1016/j.blre.2017.10.003. Epub 2017 Oct 28. Review.

PMID:
29122300
15.

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC.

J Clin Oncol. 2017 May 1;35(13):1437-1443. doi: 10.1200/JCO.2016.70.2282. Epub 2017 Feb 13.

16.

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, Loscertales J, Taylor K, Vandenberghe E, Wach M, Wagner-Johnston N, Ysebaert L, Dreiling L, Dubowy R, Xing G, Flinn IW, Owen C.

Lancet Haematol. 2017 Mar;4(3):e114-e126. doi: 10.1016/S2352-3026(17)30019-4.

PMID:
28257752
17.

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.

Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato A, Byrd JC, Awan FT, Hebart H, Garcia-Marco JA, Hill BT, Hallek M, Eisenfeld AJ, Stromatt SC, Jaeger U.

Br J Haematol. 2017 Feb;176(4):618-628. doi: 10.1111/bjh.14464. Epub 2016 Dec 15.

18.

Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.

McWilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ, Mo X, Byrd JC, Muthusamy N, Awan FT.

Oncoimmunology. 2016 Sep 9;5(10):e1226720. eCollection 2016.

19.

The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.

Jacobs RW, Awan FT, Leslie LA, Usmani SZ, Ghosh N.

Expert Rev Hematol. 2016 Dec;9(12):1177-1187. Epub 2016 Nov 14. Review.

PMID:
27791448
20.

Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2117-2125. doi: 10.1016/j.bbmt.2016.09.013. Epub 2016 Sep 19. Review.

21.

Current state of hematopoietic cell transplantation in CLL as smart therapies emerge.

Kharfan-Dabaja MA, El-Asmar J, Awan FT, Hamadani M, Ayala E.

Best Pract Res Clin Haematol. 2016 Mar;29(1):54-66. doi: 10.1016/j.beha.2016.08.001. Epub 2016 Aug 11. Review.

PMID:
27742072
22.

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, Awan FT, Hexner E, Mauro MJ, Sternberg DW, Villeneuve M, Huntsman Labed A, Stanek EJ, Hartmann K, Horny HP, Valent P, Reiter A.

N Engl J Med. 2016 Jun 30;374(26):2530-41. doi: 10.1056/NEJMoa1513098.

23.

Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.

Awan FT, Gore L, Gao L, Sharma J, Lager J, Costa LJ.

Br J Haematol. 2016 Oct;175(1):55-65. doi: 10.1111/bjh.14181. Epub 2016 Jun 13.

PMID:
27293194
24.

A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy.

Awan FT, Jones JA, Maddocks K, Poi M, Grever MR, Johnson A, Byrd JC, Andritsos LA.

Ann Hematol. 2016 Jun;95(7):1137-43. doi: 10.1007/s00277-016-2683-1. Epub 2016 Apr 27.

25.

Cure for CLL?

Awan FT.

Blood. 2016 Jan 21;127(3):274. doi: 10.1182/blood-2015-11-678532. No abstract available.

26.

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR.

N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7.

27.

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.

Rogers KA, Ruppert AS, Bingman A, Andritsos LA, Awan FT, Blum KA, Flynn JM, Jaglowski SM, Lozanski G, Maddocks KJ, Byrd JC, Woyach JA, Jones JA.

Leukemia. 2016 Feb;30(2):346-50. doi: 10.1038/leu.2015.273. Epub 2015 Oct 7.

28.
29.

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.

Brown JR, Davids MS, Rodon J, Abrisqueta P, Kasar SN, Lager J, Jiang J, Egile C, Awan FT.

Clin Cancer Res. 2015 Jul 15;21(14):3160-9. doi: 10.1158/1078-0432.CCR-14-3262. Epub 2015 Apr 3.

30.

Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.

Awan FT, Flynn JM, Jones JA, Andritsos LA, Maddocks KJ, Sass EJ, Lucas MS, Chase W, Waymer S, Ling Y, Jiang Y, Phelps MA, Byrd JC, Lucas DM, Woyach JA.

Leuk Lymphoma. 2015;56(10):2834-40. doi: 10.3109/10428194.2015.1014368. Epub 2015 Mar 11.

31.

New strategies in chronic lymphocytic leukemia: shifting treatment paradigms.

Awan FT, Byrd JC.

Clin Cancer Res. 2014 Dec 1;20(23):5869-74. doi: 10.1158/1078-0432.CCR-14-1889. Epub 2014 Oct 7. Review.

32.

Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.

Pagel JM, Spurgeon SE, Byrd JC, Awan FT, Flinn IW, Lanasa MC, Eisenfeld AJ, Stromatt SC, Gopal AK.

Br J Haematol. 2015 Jan;168(1):38-45. doi: 10.1111/bjh.13099. Epub 2014 Aug 22.

PMID:
25146490
33.

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC; LUCID trial investigators.

Br J Haematol. 2014 Nov;167(4):466-77. doi: 10.1111/bjh.13061. Epub 2014 Aug 8.

34.

Administration of anti-thymocyte globulin: a comparison of two protocols.

Clemmons AB, Hartranft ME, Kota V, Pantin J, Awan FT, Salman H, Jillella AP.

Bone Marrow Transplant. 2014 Dec;49(12):1535-7. doi: 10.1038/bmt.2014.174. Epub 2014 Aug 4. No abstract available.

PMID:
25089593
35.

PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.

El-Gamal D, Williams K, LaFollette TD, Cannon M, Blachly JS, Zhong Y, Woyach JA, Williams E, Awan FT, Jones J, Andritsos L, Maddocks K, Wu CH, Chen CS, Lehman A, Zhang X, Lapalombella R, Byrd JC.

Blood. 2014 Aug 28;124(9):1481-91. doi: 10.1182/blood-2014-05-574830. Epub 2014 Jul 7.

36.

Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?

Clemmons AB, Evans S, DeRemer DL, Awan FT.

J Oncol Pharm Pract. 2015 Dec;21(6):425-32. doi: 10.1177/1078155214541571. Epub 2014 Jul 1.

PMID:
24986792
37.

Obinutuzumab may chart the way to improved QOL for CLL patients.

Awan FT.

J Community Support Oncol. 2014 Apr;12(4):113-4.

PMID:
24971418
38.

Ibrutinib: targeting the hidden CLL.

Awan FT.

Blood. 2014 May 22;123(21):3215-6. doi: 10.1182/blood-2014-04-565333. No abstract available.

39.

A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia.

Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE, Andritsos LA, Gopal AK, Leonard JP, Eisenfeld AJ, Bannink JE, Stromatt SC, Furman RR.

Blood. 2014 Feb 27;123(9):1302-8. doi: 10.1182/blood-2013-07-512137. Epub 2013 Dec 31.

40.

Romiplostim resistance in secondary failure of platelet recovery.

DeRemer DL, Katsanevas K, Bradley A, Awan FT.

J Oncol Pharm Pract. 2013 Dec;19(4):369-72. doi: 10.1177/1078155212469640. Epub 2013 Jan 4.

PMID:
23292974
41.

Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization.

Awan FT, Kochuparambil ST, Deremer D, Cumpston A, Craig M, Jillella A, Hamadani M.

J Oncol. 2012;2012:931071. doi: 10.1155/2012/931071. Epub 2012 Apr 10.

42.

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.

Awan FT, Osman S, Kochuparambil ST, Gibson L, Remick SC, Abraham J, Craig M, Jillella A, Hamadani M.

Bone Marrow Transplant. 2012 Jan;47(1):146-8. doi: 10.1038/bmt.2011.18. Epub 2011 Feb 28. No abstract available.

PMID:
21358681
43.

How we approach patient evaluation for hematopoietic stem cell transplantation.

Hamadani M, Craig M, Awan FT, Devine SM.

Bone Marrow Transplant. 2010 Aug;45(8):1259-68. doi: 10.1038/bmt.2010.94. Epub 2010 May 17. Review.

PMID:
20479713
44.

Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.

Awan FT, Johnson AJ, Lapalombella R, Hu W, Lucas M, Fischer B, Byrd JC.

Leuk Lymphoma. 2010 Jan;51(1):27-38. doi: 10.3109/10428190903350405. Review.

45.

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM Jr, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, Caligiuri MA, Muthusamy N, Byrd JC.

Blood. 2010 Feb 11;115(6):1204-13. doi: 10.1182/blood-2009-06-229039. Epub 2009 Dec 2.

46.

Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia.

Hamadani M, Awan FT.

Hematol Oncol. 2010 Mar;28(1):3-12. doi: 10.1002/hon.915. Review.

PMID:
19645073
47.

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.

Awan FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung N, Jelinek DF, Tschumper RC, Secreto CR, Lin TS, Grever MR, Shanafelt TD, Zent CS, Call TG, Heerema NA, Lozanski G, Byrd JC, Lucas DM.

Blood. 2009 Jan 15;113(3):535-7. doi: 10.1182/blood-2008-08-173450. Epub 2008 Nov 13.

48.

Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.

Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Benson DM, Blum KA, Devine SM.

Leuk Lymphoma. 2008 Oct;49(10):1893-8. doi: 10.1080/10428190802270902.

PMID:
18949613
49.

Hematopoietic stem cell transplantation in adults with acute myeloid leukemia.

Hamadani M, Awan FT, Copelan EA.

Biol Blood Marrow Transplant. 2008 May;14(5):556-67. doi: 10.1016/j.bbmt.2008.02.019. Review.

50.

The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation.

Hamadani M, Awan FT, Devine SM.

Blood. 2008 Apr 1;111(7):3901-2. doi: 10.1182/blood-2008-01-132050. No abstract available.

Supplemental Content

Support Center